Formulation Development
Servier & X-Chem Announce Drug Discovery Collaboration
Servier and X-Chem, Inc. recently announced a partnership to identify and develop novel small molecules for the treatment of….
Kite & Oxford BioTherapeutics Establish Cell Therapy Research Collaboration
Kite, a Gilead Company, and Oxford BioTherapeutics Ltd. recently announced the companies have entered into a research collaboration to evaluate five novel targets for a….
Argenx & Zai Lab Announce Strategic Collaboration
Argenx SE and Zai Lab Limited recently announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater China, including….
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion
Catalyst Pharmaceuticals, Inc. recently announced an expansion in its strategic priorities related to portfolio planning and research and development. Catalyst also provided preliminary net revenues…
WuXi STA’s Integrated CMC Platform Supports InnoCare Orelabrutinib Approved by NMPA
STA Pharmaceutical, a WuXi AppTec Company (WuXi STA), recently announced their partner Innocare has received approval by the National Medical Products Administration of China (NMPA)…
Silo Pharma Inc. Receives $1 Million in Up Front Licensing Deal
Silo Pharma, Inc. recently announced it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the…
EMA Recommends COVID-19 Vaccine Moderna for Authorization in the EU
The EMA has recently recommended granting a conditional marketing authorization for COVID-19 Vaccine Moderna to prevent coronavirus disease 2019 (COVID-19) in people from 18 years…
Apollomics & GlycoMimetics Granted Breakthrough Therapy Designation
Apollomics, Inc. and GlycoMimetics recently announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for…
ViGeneron Signs Global Development & Commercialization Agreement With Biogen
ViGeneron GmbH recently announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat….
University of Calgary Joins the Phase 2 Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
Arch Biopartners Inc. RECENTLY announced the University of Calgary Cumming School of Medicine has joined the Phase 2 trial of its lead drug LSALT peptide (Metablok), targeting the prevention….
Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100 Million
Rhythm Pharmaceuticals, Inc. recently announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $100 million.…
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
Ocuphire Pharma, Inc. recently announced the initiation of patient recruitment and screening in late December for its LYNX-1 Phase 3 registration study evaluating the safety…
PHASTAR Announces Investment by Charterhouse Capital Partners
PHASTAR recently announced an investment made by Charterhouse Capital Partners LLP that will support PHASTAR’s growth in biometrics and geographic expansion. Charterhouse is making its…
Akston Biosciences & LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 Vaccine
Akston Biosciences and LakePharma recently announced they have established a strategic partnership in which LakePharma will manufacture commercial quantities of Akston’s adjuvated COVID-19 vaccine candidate (AKS-452),…
Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility
Oncorus, Inc. recently announced it has signed a 15-year lease to build a state-of-the-art, 88,000-square-foot Good Manufacturing Practice (GMP) viral immunotherapy clinical manufacturing facility in…
Inozyme Pharma Announces Authorization to Proceed in US & UK With Phase 1/2 Clinical Trial
Inozyme Pharma, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application and that the United Kingdom Medicines and Healthcare…
EyePoint Pharmaceuticals Announces $15.7-Million Equity Investment
EyePoint Pharmaceuticals, Inc. recently announced Ocumension Therapeutics has made a $15.7-million equity investment in EyePoint. Under the terms of the agreement, Ocumension has purchased approximately…
Ajinomoto Bio-Pharma Services & Revance Therapeutics Announce Manufacturing Agreement
Ajinomoto Bio-Pharma Services and Revance Therapeutics, Inc. recently announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for….
Vectura Earns $11-Million Milestone as Hikma Receives US FDA Approval for Generic Advair DiskusR
Vectura Group plc recently announced its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder)….
Aurinia & Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Aurinia Pharmaceuticals Inc. and Lonza recently announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build….
